Blocking Type I Interferon Production: A New Therapeutic Option to Reduce the HIV-1-Induced Immune Activation
Highly active antiretroviral therapy has dramatically improved the morbidity and mortality of HIV-1-infected individuals. A total of 25 licensed drugs provide the basis for an optimized virus-suppressive treatment of nearly each subject. The promises of immune reconstitution and normal life expectan...
Saved in:
Main Authors: | Moritz Ries, Kathrin Pritschet, Barbara Schmidt |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2012/534929 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Type I Interferon at the Interface of Antiviral Immunity and Immune Regulation: The Curious Case of HIV-1
by: Adriano Boasso
Published: (2013-01-01) -
Manipulation of Type I Interferon Signaling by HIV and AIDS-Associated Viruses
by: Buyuan He, et al.
Published: (2019-01-01) -
Interferon Induced Focal Segmental Glomerulosclerosis
by: Yusuf Kayar, et al.
Published: (2016-01-01) -
Therapeutic Options in the Treatment and Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Ulceration
by: Malcolm C Champion
Published: (1990-01-01) -
Therapeutic Options for the Management of the Cardiorenal Syndrome
by: Katerina Koniari, et al.
Published: (2011-01-01)